Catalyst Biosciences, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.
The company announced in the following Press release that, “CB 2679d has shown significantly higher potency in pre-clinical studies versus other FIX products on the market and in development. Based on data from well-validated animal models of hemophilia, CB 2679d may provide hemophilia B patients with a viable subcutaneous prophylactic therapy.” Read the full article.
Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company. It focuses on creating and developing novel medicines to address serious medical conditions for patients who need new or better treatment options. The company was founded on August 5, 2002 and is headquartered in South San Francisco, CA. [Source: MarketWatch]
Company Website: http://www.catalystbiosciences.com